TREATMENT OF PROSTATIC-CARCINOMA AND RELA PSE TO HORMONAL TREATMENT WITH ST52

Objective: Stilboestrol phosphate (ST 52) was evaluated on pain, gener al status, life expectancy and PSA, in a retrospective study of patien ts with prostatic carcinoma and relapse to hormonal treatment. Materia l and methods: 32 patients were treated by infusion of Stilboestrol ph osphate at a daily escalating dose from 1.2 to 3 g over a period of 10 days, then subsequently oral administration, Results, Minor complicat ions, especially nausea were observed in 12 cases but no major complic ation or interruption of treatment. Improvement for pain alone or with general status was obtained in 50% (16 cases) at 3 months, but at one year only 10% were still improved. Median survival was 8 months, with 19.4 months for responders at the end of infusions and 4.2 months for non-responders-respectively. Conclusion: Stilboestrol phosphate can o btain a clinical response with low morbidity when relapse to hormonal treatment occurs. Infusion responders have a better life expectancy.